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A VCP inhibitor substrate trapping approach 
(VISTA) enables proteomic profiling of 
endogenous ERAD substrates
ABSTRACT Endoplasmic reticulum (ER)–associated degradation (ERAD) mediates the prote-
asomal clearance of proteins from the early secretory pathway. In this process, ubiquitinated 
substrates are extracted from membrane-embedded dislocation complexes by the AAA 
ATPase VCP and targeted to the cytosolic 26S proteasome. In addition to its well-established 
role in the degradation of misfolded proteins, ERAD also regulates the abundance of key 
proteins such as enzymes involved in cholesterol synthesis. However, due to the lack of gen-
eralizable methods, our understanding of the scope of proteins targeted by ERAD remains 
limited. To overcome this obstacle, we developed a VCP inhibitor substrate trapping ap-
proach (VISTA) to identify endogenous ERAD substrates. VISTA exploits the small-molecule 
VCP inhibitor CB5083 to trap ERAD substrates in a membrane-associated, ubiquitinated 
form. This strategy, coupled with quantitative ubiquitin proteomics, identified previously 
validated (e.g., ApoB100, Insig2, and DHCR7) and novel (e.g., SCD1 and RNF5) ERAD 
substrates in cultured human hepatocellular carcinoma cells. Moreover, our results indicate 
that RNF5 autoubiquitination on multiple lysine residues targets it for ubiquitin and VCP- 
dependent clearance. Thus, VISTA provides a generalizable discovery method that expands 
the available toolbox of strategies to elucidate the ERAD substrate landscape.
INTRODUCTION
The endoplasmic reticulum (ER) mediates the folding, modification, 
and deployment of one-third of the cellular proteome. Proteins that 
fail to fold or lack requisite oligomeric binding partners are degraded 
through ER-associated degradation (ERAD), a ubiquitin-dependent 
process that targets substrates to the 26S proteasome for proteoly-
sis (Olzmann et al., 2013; Christianson and Ye, 2014; Ruggiano et al., 
2014). A modular network of ERAD machinery coordinates substrate 
recognition and dislocation (also known as retrotranslocation) from 
the ER lumen or membrane into the cytoplasm (Carvalho et al., 
2006; Christianson et al., 2011). ER-resident E3 ubiquitin ligases 
mediate substrate ubiquitination, which serves both as a protea-
somal targeting signal and a binding interface that facilitates sub-
strate extraction by the homohexameric AAA ATPase VCP (also 
known as p97) and its associated ubiquitin-binding cofactors (e.g., 
UFD1L and NPLOC4; Olzmann et al., 2013; Ye et al., 2017). VCP-
mediated ATP hydrolysis generates the necessary force for the ex-
traction of the ubiquitinated substrate, which is partially unfolded as 
it is threaded through the VCP central pore (Ernst et al., 2011; Blythe 
et al., 2017; Bodnar and Rapoport, 2017).
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reductase, Insig1/2), secreted proteins (e.g., 
ApoB100, proAVP), and plasma membrane 
proteins (e.g., KAI1, CD147, pre–B cell re-
ceptor, SLC1A5, SLC38A2; Song et al., 
2005; Lee et al., 2006; Tsai et al., 2007; Liu 
et al., 2012; Tyler et al., 2012; Fisher et al., 
2014; Jeon et al., 2015; Ji et al., 2016; Shi 
et al., 2017; To et al., 2017). Thus, by influ-
encing the abundance of ER-resident pro-
teins and secreted proteins, ERAD impacts 
both cell autonomous and noncell autono-
mous processes.
Despite the importance of ERAD in pro-
tein quantity control, our understanding of 
the endogenous substrates targeted by 
ERAD remains limited. This surprising dearth 
of knowledge is in part due to the lack of 
generalizable methods to identify endoge-
nous ERAD substrates in human cells. Here, 
we describe a quantitative ubiquitin pro-
teomics strategy termed VCP inhibitor sub-
strate trapping approach (VISTA) to identify 
endogenous ERAD substrates.
RESULTS AND DISCUSSION
VCP inhibition traps ubiquitinated 
NHK in complex with the Hrd1 E3 
ubiquitin ligase
A principal function of VCP is to extract ubiq-
uitinated ERAD substrates from the ER into 
the cytosol for proteasomal degradation 
(Bagola et al., 2011; Ye et al., 2017). CB5083 
is a small-molecule VCP inhibitor that im-
pairs the degradation of several integral 
membrane ERAD substrates, including 
CD147 (To et al., 2017), c18orf32 (Bersuker 
et al., 2018), and overexpressed TCRα-GFP 
(Anderson et al., 2015). In addition, incuba-
tion with CB5083 results in the accumulation 
of ubiquitinated proteins (Anderson et al., 
2015; Gendron et al., 2016). We reasoned 
that acute pharmacological inhibition of VCP 
with CB5083 could be exploited to stabilize 
or “trap” ERAD substrates in a ubiquiti-
nated, membrane-bound form (Figure 1A).
As a first test of the utility of CB5083 to trap ERAD substrates, 
we examined the impact of CB5083 treatment on the well-charac-
terized luminal ERAD substrate NHK. In a translation shut-off assay, 
the half-life HA-tagged NHK (NHK-HA) was greatly extended in the 
presence of CB5083 (Figure 1, B and C), demonstrating that incu-
bation with CB5083 impairs the degradation of a luminal ERAD 
substrate. Dislocation and ubiquitination of NHK are mediated by 
a membrane-embedded, macromolecular complex containing the 
E3 ubiquitin ligase Hrd1 (Christianson et al., 2008; Hosokawa et al., 
2008). Thus, we sought to test the hypothesis that VCP inhibition 
traps polyubiquitinated NHK in complex with Hrd1. CB5083 treat-
ment led to both an increase in ubiquitinated proteins in cell lysates 
(i.e., Input) as well as an increased association of NHK-HA and ubiq-
uitinated proteins with S-tagged Hrd1 (Hrd1-S), consistent with im-
paired clearance of ubiquitin-conjugated proteins (Figure 1D). A 
portion of NHK-HA associated with Hrd1-S migrated as a high- 
molecular-weight smear that was sensitive to incubation with the 
A canonical role of ERAD is the clearance of misfolded proteins 
(i.e., quality control), such as the ∆F508 mutant cystic fibrosis trans-
membrane conductance regulator in cystic fibrosis and the truncated 
null Hong Kong (NHK) variant of α-1 antitrypsin in α-1 antitrypsin 
deficiency (Guerriero and Brodsky, 2012). The identification of dis-
ease-associated mutant proteins as ERAD substrates has provided 
useful tools to study the mechanisms of ERAD (Needham and Brod-
sky, 2013). A less appreciated role of ERAD is in regulating the levels 
of endogenous proteins (i.e., quantity control; Hegde and Ploegh, 
2010; Stevenson et al., 2016; Qi et al., 2017). For example, ERAD 
controls the flux through the cholesterol synthesis pathway by 
facilitating the sterol-regulated degradation of HMG CoA reductase 
(Song et al., 2005) and squalene monooxygenase (Gill et al., 2011; 
Foresti et al., 2013). ERAD quantity control has also been implicated 
in a wide variety of pathological conditions, such as cancer, hepatic 
steatosis, obesity, diabetes insipidus, and immune system function, 
through its ability to degrade ER-resident proteins (e.g., HMG CoA 
FIGURE 1: VCP inhibition traps the ERAD substrate NHK in complex with the E3 ligase Hrd1. 
(A) Schematic of VISTA. Pharmacological inhibition of VCP with CB5083 prevents the dislocation 
of ubiquitinated ERAD substrates. (B) HEK293 cells expressing NHK-HA were incubated with 
75 µM emetine and either vehicle or 5 µM CB5083 for the indicated time points. SDS lysates 
were analyzed by immunoblotting for the indicated targets. (C) The relative levels of NHK-HA 
(panel B) were quantified and presented as a percentage of the levels at time 0 h ± SEM 
(n = 3). (D) HEK293 cells stably expressing Hrd1-S were transiently transfected with NHK-HA, 
treated with vehicle or 5 µM CB5083, subject to affinity purification with S-protein (S-prot) 
agarose, and SDS lysates analyzed by immunoblotting; n = 3. (E) HEK293 cells stably expressing 
NHK-HA were treated with vehicle or 5 µM CB5083, subject to affinity purification with 
anti-HA–conjugated agarose, and SDS lysates analyzed by immunoblotting. Asterisk indicates a 
USP2cc-reactive band. AP, affinity purification; IP, immunoprecipitation; S-prot, S-protein; Ubn, 
ubiquitinated; endo, endogenous; Em., emetine.
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et al., 2016), 7-dehydrocholesterol reductase (DHCR7; Prabhu 
et al., 2016), and insulin-induced gene 2 (Insig2; Liu et al., 2012). 
Following CB5083 treatment, increases in the levels of two diGly 
peptides in ApoB100 (K196, 13.805-fold increase; K2697, 9.249-
fold increase), a cluster of three diGly peptides in DHCR7 (K4, 
3.602-fold increase; K11, 3.497-fold increase; K13, 3.861-fold in-
crease), and one diGly peptide in Insig2 (K221, 7.27-fold increase) 
were detected (Figure 2, G–L), suggesting that modification of 
these lysines by ERAD E3 ligases targets these substrates to the 
proteasome. Other reported endogenous ERAD substrates may 
not have been identified due to their low abundance in HepG2 
cells or their regulated degradation under specific conditions, such 
as IP3 receptor degradation following ligand binding (Wojcikiewicz 
et al., 2009) or HMG CoA reductase degradation following sterol 
accumulation in ER membranes (Jo and Debose-Boyd, 2010). 
Although it is unlikely to be a comprehensive list, these data dem-
onstrate the ability of ERAD-VISTA to detect known and candidate 
endogenous ERAD substrates.
Gene ontology (GO) enrichment analysis of candidate ERAD 
substrates revealed an expected enrichment in proteins that are 
known to localize to cell membranes (e.g., ER and plasma mem-
brane) as well as complexes associated with various components of 
the ERAD network (Figure 3A and Supplemental Table S2). Indeed, 
analysis of the annotated localizations revealed that 59.2% of the 
candidate substrates were predicted to be present in, or transit 
through, the secretory pathway (Supplemental Table S3). A smaller 
portion of the candidate substrates are annotated as mitochondrial 
(8.3%), lysosomal (0.8%), and vesicular (1.7%; Supplemental Table 
S3), indicating a high degree of enrichment in ubiquitinated secre-
tory proteins. We observed an enrichment in proteins involved 
amino acid transport, protein catabolism, protein folding, and cho-
lesterol and fatty acid biosynthesis (Figure 3B and Supplemental 
Table S2). This functional diversity reflects the wide array of potential 
ERAD substrates transiting the early secretory pathway and is con-
sistent with a broad cellular role for ERAD through its regulation of a 
multitude of targets.
Degradation of endogenous SCD1 and RNF5 requires VCP, 
ubiquitin conjugation, and the proteasome
We next sought to validate select putative ERAD substrates from 
our candidate list. Two candidate substrates were selected for 
further analysis. Stearoyl-CoA desaturase (SCD1) is an ER-localized 
enzyme that catalyzes the production of monounsaturated fatty 
acids from saturated fatty acids (Ntambi and Miyazaki, 2003). Lev-
els of a diGly-modified lysine in the cytosolic C-terminus of SCD1 
increased in response to CB5083 (K341, 10.621-fold increase; 
Figure 4, A and B). Overexpressed SCD1 in CHO-K1 and HeLa cells 
as well as endogenous SCD1 in NIH3T3-L1 cells are degraded by 
the proteasome (Mziaut et al., 2000; Kato et al., 2006). However, 
whether VCP is required for SCD1 degradation and whether en-
dogenous SCD1 is degraded in HepG2 cells remains unknown. 
Consistent with SCD1 being a direct substrate of VCP, CB5083 
treatment increased the amount of VCP associated with S-tagged 
SCD1 (SCD1-S; Figure 4C). Moreover, the degradation of SCD1 
was impaired by CB5083, the proteasome inhibitor MG132, and an 
inhibitor of the E1 ubiquitin-activating enzyme MLN7243 (Figure 4, 
D and E). We observed an anti-SCD1 immunoreactive, lower-mole-
cular-weight band that was partially degraded in control cells and 
exhibited a modest accumulation in the presence of the inhibitors 
(Figure 4D). This band was depleted by multiple small interfering 
RNAs (siRNAs) targeting SCD1 (Supplemental Figure S3), confirm-
ing that it is a fragment of SCD1, but its functional significance is 
catalytic core of the deubiquitinating enzyme USP2 (USP2cc; Figure 
1D), indicating that this fraction of NHK-HA in complex with Hrd1-S 
is ubiquitinated. Furthermore, immunoprecipitations of NHK-HA 
indicate that CB5083 increases the association of NHK-HA with 
components of the Hrd1 complex, including Hrd1, SEL1L, OS-9, 
and XTP3-B (Figure 1E). These proof-of-principle experiments 
demonstrate that CB5083 treatment traps a known ERAD substrate 
in a ubiquitinated form, in complex with its membrane-embedded 
degradation apparatus. We also observed that CB5083 treatment 
resulted in the accumulation of the core glycosylated form of inte-
gral membrane protein CD147 (CD147[CG]), an endogenous ERAD 
substrate (Tyler et al., 2012; To et al., 2017), but it caused only a 
small increase in the association of CD147(CG) with Hrd1-S (Sup-
plemental Figure S1). This may reflect differences in the mode of 
interaction between Hrd1 and its luminal and integral membrane 
substrates. For example, under periods of VCP impairment, an in-
tegral membrane substrate may be preferentially released into the 
surrounding membrane to prevent prolonged occupancy of the 
Hrd1 ubiquitination complex.
Global analysis of trapped, ubiquitinated proteins identifies 
endogenous ERAD substrates in HepG2 liver cells
To identify endogenous ERAD substrates, VCP inhibition was cou-
pled with quantitative ubiquitin proteomics in a method we refer to 
as ERAD-VISTA (Figure 2A). Cells were labeled by stable isotope 
labeling with amino acids in cell culture (SILAC) and treated with ve-
hicle (light) or CB5083 (heavy). Beads conjugated with antibodies 
that recognize peptides bearing diglycine (diGly)-modified lysine 
residues (i.e., a tryptic ubiquitin remnant; Kim et al., 2011; Gendron 
et al., 2016) were used to affinity purify ubiquitin-modified peptides 
from membrane fractions for proteomic analysis. Consistent with the 
trapping of ubiquitinated proteins, CB5083 treatment resulted in 
greater levels of polyubiquitinated proteins in cell lysate and the ER-
enriched membrane fraction (Figure 2B). Proteomic analysis of diGly-
modified peptides purified from membrane fractions identified a 
total of 5573 diGly-modified peptides across four independent ex-
periments, corresponding to 478 proteins (Supplemental Table S1). 
There was some variability in the number of unique diGly peptides 
identified (Figure 2C and Supplemental Table S1), which may be 
due to different batches of diGly beads. Experiments 3 and 4 were 
performed with the same batch of beads and were very similar with 
respect to the number of unique diGly peptides identified in each 
experiment (Figure 2C and Supplemental Table S1). diGly-modified 
peptides with SILAC ratios greater than 2.0 (123 proteins), indicating 
an accumulation of the ubiquitinated peptide during VCP inhibition, 
were considered candidate ERAD substrates (Supplemental Figure 
S2 and Supplemental Table S1). A single diGly modification was 
identified for the majority of proteins (68.2% for all proteins, 59.2% 
for proteins with SILAC ratio > 2), but a fraction of the proteins were 
also observed that contained two diGly modifications (18.8% for all 
proteins, 20.8% for proteins with SILAC ratio > 2) or three diGly mod-
ifications (9.6% for all proteins, 12.5% for proteins with SILAC ratio > 
2; Figure 2D). As expected, a large number of ubiquitin diGly pep-
tides were identified, most of which corresponded to K48 and K63 
diGly-modified peptides (Figure 2E). In all four experiments, K11, 
K33, and K48 diGly peptides showed a strong increase, consistent 
with a role in protein degradation (Figure 2F). In contrast, the amount 
of K63 diGly peptide was mostly unchanged and the amount of K27 
diGly peptide showed a decrease (Figure 2F).
Among the list of candidate substrates (Supplemental Table S1), 
three bona fide endogenous ERAD substrates were detected: Apo-
lipoprotein B100 (ApoB100; Ginsberg and Fisher, 2009; Stevenson 
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FIGURE 2: Global analysis of trapped, ubiquitinated proteins identifies validated and candidate ERAD substrates in 
cultured liver cells. (A) Schematic of ERAD-VISTA experimental workflow. (B) HepG2 cells treated with vehicle or 5 µM 
CB5083 were fractionated by differential centrifugation and equal volumes analyzed by immunoblotting; n = 3. (C) Venn 
diagram comparing unique diGly-modified peptides identified from the four independent experiments. (D) Bar graph 
indicating the number of unique diGly sites identified for all proteins (blue) and for proteins with a SILAC ratio > 2 (red). 
(E) Pie chart illustrating the relative abundance of diGly-modified ubiquitin peptides, based on total spectral counts. 
(F) Log2 SILAC peptide ratios for individual diGly-modified peptides from ubiquitin. (G–I) Protein domain structure and 
the identified diGly-modified lysine residues for three validated endogenous ERAD substrates (ApoB100, DHCR7, and 
Insig2). TM: transmembrane domain. (J–L) Log2 SILAC peptide ratios for individual diGly-modified peptides from 
ApoB100 (J), DHCR7 (K), and Insig2 (L). Colors indicate the experiment from which the diGly peptide was identified, as 
in panel F. Mem., membrane; Ubn, ubiquitinated; Exp., experiment; TSC, total spectral counts. Asterisk indicates that 
the diGly peptide was not detected in that experiment. See also Supplemental Table S1.
unclear at this time. Our data suggest that SCD1 is constitutively 
degraded by a VCP-dependent ERAD pathway in HepG2 cells. This 
is similar to the SCD1 yeast orthologue OLE1, which undergoes 
degradation through an ERAD pathway that requires the VCP 
orthologue CDC48 (Braun et al., 2002). Future experiments will 
explore if SCD1 degradation is regulated by the metabolic state of 
the cell, such as fluctuations in the ratio of unsaturated to saturated 
fatty acids.
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with three to four particularly prominent bands that were separated 
by ∼8 kDa (i.e., the size of ubiquitin) and that increased following 
CB5083 treatment (Figure 5, C and D). These bands were greatly 
reduced by incubation with USP2cc, indicating that these represent 
ubiquitinated forms of RNF5 (Figure 5, C and D). The ubiquitinated 
RNF5 species were mostly absent in the C42A mutant RNF5 (Figure 
5, C and D). We considered that the small amount of ubiquitinated 
S-RNF5(C42A) may be due to ubiquitination S-RNF5(C42A) by 
endogenous RNF5. Indeed, FLAG-HA-RNF5 coprecipitated with S-
RNF5, indicating the presence of RNF5 homo-oligomers (Supple-
mental Figure S4B). To examine the possibility of trans-molecular 
RNF5 autoubiquitination, we expressed S-RNF5(C42A) in RNF5 
knockout (KO) cells generated using CRISPR/Cas9 (Supplemental 
Figure S5). Similar to the control cells, S-RNF5(C42A) still exhibited 
a small amount of laddering in the RNF5 KO cells, indicating that 
the endogenous RNF5 does not contribute to the ubiquitination of 
S-RNF5(C42A) (Supplemental Figure S5B). Our data are in very 
good agreement with previous in vitro studies (Matsuda et al., 2001) 
and suggest RNF5 autoubiquitination is a cis-molecular reaction. 
The residual ubiquitination of S-RNF5(C42A) must be mediated by 
an unknown E3 ligase.
Our proteomics results indicate that all four lysines in RNF5 are 
ubiquitinated and are sensitive to VCP inhibition (Figure 4, F and G, 
and Supplemental Table S1). To explore the contribution of these 
lysines to RNF5 degradation we generated constructs harboring ly-
sine-to-arginine substitutions. Although there was a small decrease 
in the ubiquitination of S-RNF5(K75R) and S-RNF(K86R), all S-RNF5 
single lysine mutants were still ubiquitinated (Figure 5E). Therefore, 
we generated an S-RNF5 construct in which all four lysines were 
substituted with arginine (4K-R). The 4K-R mutant exhibited a dra-
matic reduction in ubiquitination (Figure 5, F and G). A very small 
amount of ubiquitinated S-RNF5(4K-R) was visible, suggesting that 
RNF5 may either ubiquitinate noncanonical residues (e.g., serine) or 
one of the lysines in the S-tag. Although the S-tag contains two 
lysine residues, the ubiquitination of RNF5 was nearly abolished in 
the 4K-R mutant. This may indicate a structural preference for the 
Another candidate ERAD substrate identified using VISTA is 
RNF5, an ERAD E3 ligase that mediates the clearance of misfolded 
proteins (Younger et al., 2006; Morito et al., 2008; Grove et al., 
2011) and controls the stability of proteins involved in a variety of 
cellular processes such as autophagy (Kuang et al., 2012), amino 
acid transport (Jeon et al., 2015), and viral immunity (Zhong et al., 
2010). We identified four diGly-modified lysines that clustered 
within the cytosolic N-terminus of RNF5 and increased following 
CB5083 treatment (K68, 4.029-fold increase; K75, 7.038-fold 
increase; K86, 6.307-fold increase; K93, 8.339-fold increase; Figure 
4, F and G). Similar to SCD1-S, CB5083 treatment increased 
the amount of VCP that coprecipitated with S-RNF5 (Figure 4H). 
Translation shut-off experiments indicated that the degradation of 
endogenous RNF5 was impaired by CB5083, MG132, and MLN7243 
(Figure 4, I and J). Together, our findings indicate that two of the 
candidate ERAD substrates in HepG2 cells identified by ERAD-
VISTA, SCD1 and RNF5, are constitutively degraded by a VCP- and 
ubiquitin-dependent ERAD pathway.
Autoubiquitination targets RNF5 to the ERAD pathway in 
HepG2 cells
Maltose-binding protein (MBP)–tagged RNF5 autoubiquitinates in 
vitro through an intramolecular reaction that requires an intact RING 
finger domain (Matsuda et al., 2001). However, whether RNF5 aut-
oubiquitinates in cells and whether this activity contributes to its 
proteasomal clearance has not been examined. We generated an 
S-tagged RNF5 construct containing a cysteine-to-alanine substitu-
tion (C42A), which disrupts the RING finger and abrogates its cata-
lytic activity (Matsuda et al., 2001). When transfected into HepG2 
cells, S-RNF5(WT) overexpression was low (Supplemental Figure 
S4A) and the S-RNF5(C42A) exhibited a threefold increase in pro-
tein levels relative to its wild-type counterpart (Figure 5, A and B). 
Inhibitors of ERAD increased the steady-state levels of wild-type 
RNF5, but not S-RNF5(C42A) (Figure 5, A and B), indicating that 
RNF5 ubiquitination activity is required for its degradation. Affinity 
purification of S-RNF5(WT) revealed a laddering of RNF5 bands, 
FIGURE 3: Gene ontology analysis of candidate ERAD substrates. (A, B) DAVID and REVIGO were used to identify 
enriched GO terms, cellular component (A) or biological function (B), within the candidate ERAD substrate list. 
Cytoscape networks were generated by REVIGO. Circle size indicates the frequency of the GO term in the GO 
annotation database, edge thickness is proportional to the degree of GO term similarity, and color indicates the p value 
(red being more significant). See also Supplemental Table S2.
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FIGURE 4: Endogenous SCD1 and RNF5 are degraded via a VCP- and ubiquitin-dependent proteasomal pathway. 
(A) Diagram of SCD1 protein structure, with detected diGly-modified lysine residue indicated. (B) Log2 SILAC peptide 
ratios for individual diGly-modified peptides from SCD1. (C) HepG2 cells expressing SCD1-S were treated with 
vehicle or 5 µM CB5083, subject to affinity purification with S-protein (S-prot) agarose, and SDS lysates analyzed by 
immunoblotting; n = 3. (D, E) HepG2 cells were treated with 75 µM emetine and 5 µM CB5083, 10 µM MG132, or 10 µM 
MLN7243 to disrupt various components of ERAD. SCD1 protein stability was assessed via immunoblotting (D) and 
relative levels quantified (E). Graphical data are expressed as mean ± SEM (n = 3–6 per group). (F) Diagram of RNF5 
protein structure, with detected diGly-modified lysine residues indicated. (G) Log2 SILAC peptide ratios for individual 
diGly-modified peptides from RNF5. (H) HepG2 cells expressing S-RNF5 were treated with vehicle or 5 µM CB5083, 
subject to affinity purification with S-protein (agarose, and SDS lysates analyzed by immunoblotting) (n = 3). (I, J) HepG2 
cells were treated with 75 µM emetine and 5 µM CB5083, 10 µM MG132, or 10 µM MLN7243 to disrupt various 
components of ERAD. RNF5 protein stability was assessed via immunoblotting (I) and relative levels quantified 
(J). Graphical data are expressed as mean ± SEM (n = 3–6 per group). TM: transmembrane domain. S-prot, S-protein; 
Exp., experiment; Em., emetine. Asterisk indicates that the diGly peptide was not detected in that experiment. See also 
Supplemental Table S1.
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function (e.g., fusions of E3 ligases to tandem ubiquitin-binding 
domains [Mark et al., 2014, 2016] or to ubiquitin [O’Connor et al., 
2015]). 4) The method measures changes in substrate ubiquitination 
rather than steady-state protein levels (e.g., steady-state SILAC 
[Foresti et al., 2014] or GFP-based global protein profiling [Yen and 
Elledge, 2008; Yen et al., 2008]), thereby facilitating substrate identi-
fication even when only a small fraction is ubiquitinated and 
degraded. A limitation of ERAD-VISTA is that it relies on diGly ubiq-
uitin proteomics which may impact reproducibility due to stochastic 
sampling, especially for low-abundance targets (Ordureau et al., 
2015). Thus, achieving comprehensive assessments of the ERAD 
substrate landscape is a challenge. However, depth and coverage 
may be improved by employing recent improvements in diGly 
methodologies involving the fractionation of peptides using strong 
cation exchange chromatography before immunoaffinity purification 
(Na et al., 2012; Udeshi et al., 2012). It is also important to note that 
because the diGly approach is specific to diGly-modified lysines, it 
will not identify ubiquitination on nonlysine residues such as serine 
(Shimizu et al., 2010). An additional limitation of ERAD-VISTA is that 
some CB5083-sensitive ubiquitination events might not target the 
modified protein for degradation and may instead reflect regulatory 
ubiquitination, such as the ubiquitin-dependent regulation of protein 
cluster of 4-lysine residues over the lysines in the N-terminal S-tag. 
It is notable that S-RNF5(4K-R), despite being no longer ubiquiti-
nated, still coprecipitated ubiquitinated proteins in the presence of 
CB5083 (Figure 5F). This was in contrast to the inactive S-
RNF5(C42A), which did not coprecipitate ubiquitinated proteins 
(Figure 5C). These results suggest that the S-RNF5(4K-R) mutant 
uncouples RNF5 catalytic activity and autoubiquitination. This un-
coupling mutant could be useful for exploring the functional impor-
tance of RNF5 degradation.
In summary, we have developed a new global approach for the 
identification of endogenous ERAD substrates. This approach identi-
fied known (ApoB100, DHCR7, and Insig2) and novel (SCD1 and 
RNF5) substrates. ERAD-VISTA has several important benefits over 
previous strategies to study ubiquitinated substrates: 1) The method 
uses endogenous ubiquitin and does not require overexpression of 
tagged ubiquitin (e.g., his-ubiquitin [Hitchcock et al., 2003; Peng 
et al., 2003; Kirkpatrick et al., 2005]). 2) The method does not require 
in-depth knowledge and/or genetic manipulation of the degradation 
pathway (e.g., proteomic analyses of tagged E3 ligase complexes 
[Gao et al., 2011; Tan et al., 2011, 2013; Harper and Tan, 2012] or 
tagged substrate delivery factors [Tyler et al., 2012]). 3) The method 
does not require expression of chimeric proteins that could affect 
FIGURE 5: RNF5 autoubiquitination targets it for ERAD. (A) HepG2 cells transfected with S-RNF5(WT) and 
S-RNF5(C42A) were treated as indicated and lysates analyzed by immunoblotting. (B) Densitometric quantification of 
S-RNF5 (panel A). Data are expressed as mean ± SEM (n = 4 per group). (C) HepG2 cells transfected with S-RNF5(WT) 
and S-RNF5(C42A) were treated for 6 h with vehicle or 5 µM CB5083. S-tagged proteins were affinity purified, 
incubated in the presence and absence of USP2cc, and analyzed by immunoblotting. (D) Densitometric quantification of 
S-RNF5 (panel C). (E) HepG2 cells expressing S-RNF5(WT) or S-RNF5(C42A) were treated for 6 h with vehicle or 5 µM 
CB5083. S-tagged proteins were affinity purified, incubated in the presence or absence of USP2cc, and analyzed by 
immunoblotting. (F) HepG2 cells expressing S-RNF5(WT) or S-RNF5(4K-R) were treated for 6 h with vehicle or 5 µM 
CB5083. S-tagged proteins were affinity purified, incubated in the presence or absence of USP2cc, and analyzed by 
immunoblotting. (G) Densitometric quantification of S-RNF5 affinity purified from CB5083 treated HepG2 cells (panel F). 
Btz: bortezomib; Ubn, ubiquitinated; S-prot, S-protein. AU: arbitrary units. Asterisk indicates a USP2cc-reactive band. 
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centrifuged (500 × g, 5 min, two times) to remove unbroken cells. 
The remaining supernatant was then centrifuged (20,000 × g, 30 min 
at 4°C) to separate heavy membrane and cytosolic fractions. The 
resulting pellet (membrane) was then reconstituted to its corre-
sponding cytosolic fraction volume using either HLM buffer (for im-
munoblotting) or 8M urea lysis buffer (for diGly enrichment, details 
below). For immunoblotting, SDS was then added to achieve a final 
detergent concentration of 1% and equal volumes were analyzed.
Affinity purification
Cells were collected and washed twice using ice-cold PBS. Cells 
were resuspended in immunoprecipitation (IP) lysis buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% digitonin [EMD Millipore]) con-
taining protease inhibitor tablets (Thermo Fisher Scientific) and gen-
tly rotated for 30 min at 4°C. Lysates were centrifuged (20,000 × g, 
10 min) and soluble protein (supernatant) transferred to new tubes. 
Supernatant protein concentration was then determined using the 
BCA assay (Thermo Fisher Scientific) according to the manufactur-
er’s instructions.
S-protein agarose bead slurry (25 µl bead bed/mg lysate; EMD 
Millipore) was washed two times with IP lysis buffer followed by 
one time with IP buffer containing 1% digitonin. Beads were then 
mixed with equivalent amounts of supernatant (2 h rotating, 4°C), 
washed three times with IP lysis buffer containing 0.1% digitonin, 
and proteins eluted with Laemmli buffer for immunoblotting. 
Where indicated, affinity-purified proteins were treated with 1 µg 
of USP2cc (Boston Biochem) for 1 h at 37°C before elution from 
the beads.
Immunoblotting
Cells were washed with PBS and lysed in 1% SDS. Protein quantity 
was determined using a bicinchoninic acid assay (Thermo Fisher 
Scientific). Normalized cell lysates in Laemmli sample buffer were 
heated at 65°C for 5 min and resolved on 4–20% SDS–PAGE gradi-
ent gels (Bio-Rad Laboratories). Gels were transferred to nitrocellu-
lose membrane (Bio-Rad Laboratories), blocked in PBS containing 
0.1% Tween-20 (PBST) and 5% milk, and then incubated with 
primary antibody for either 2 h at room temperature or overnight 
at 4°C. Blots were then washed and incubated with secondary anti-
bodies in PBST. Following washing PBST, blots were visualized using 
the LI-COR Odyssey Imaging System. Densitometry analyses were 
performed using the UN-SCAN-IT gel analysis (version 6.1; Silk 
Scientific) or ImageJ (version 1.49b; National Institutes of Health, 
Bethesda, MD) software.
Enrichment of diGly-modified peptides
Cells were cultured in SILAC DMEM lacking lysine and arginine, 
supplemented with 10% dialyzed FBS and the appropriate amino 
acids: light media—l-arginine (Arg0) and l-lysine (Lys0; Sigma- 
Aldrich) or heavy media—l-arginine (Arg0) and 13C615N2-l-lysine 
(Lys8; Cambridge Isotope Laboratories). Samples were then pro-
cessed for diGly immunopurification (Kim et al., 2011). Following a 
6 h treatment with DMSO (light) or 5 µM CB5083 (heavy), mem-
brane fractions were collected, solubilized in urea lysis buffer (8 M 
urea, 50 mM Tris-HCl, pH 8.0, 50 mM NaCl), reduced with 10 mM 
dithiothreitol (Thermo Fisher Scientific), and alkylated with 25 mM 
iodoacetamide (Thermo Fisher Scientific). Equal amounts of protein 
totaling 5–10 mg from the membrane fractions were combined, 
diluted with 50 mM Tris-HCl, pH 8.0, 4 M urea, and digested over-
night with 2 µg/mg LysC (Wako Laboratory Chemicals). Proteins 
were further diluted to 1.6 M urea and digested for 24 h with 10 µg/
mg mass spectrometry grade trypsin (Thermo Fisher Scientific). 
complexes (Hoppe et al., 2000; Rape et al., 2001; Ramanathan and 
Ye, 2012). Thus, the candidate ERAD substrate must be validated 
with traditional approaches. ERAD-VISTA expands the available tool-
box of strategies for probing the ERAD substrate landscape in differ-
ent cell types and under different conditions (e.g., ER stress). 
MATERIALS AND METHODS
Plasmids, antibodies, and reagents
The NHK-HA and Hrd1-S plasmids used were previously described 
(To et al., 2017). The S-RNF5 plasmid in a pcDNA3.1(+) backbone 
was a kind gift from Ron Kopito (Stanford University), and the FLAG-
HA-RNF5 plasmid in a pcDNA5/FRT/TO backbone was a kind 
gift from John Christianson (Ludwig Institute for Cancer Research, 
University of Oxford). S-RNF5 lysine-to-arginine and cysteine-to-ala-
nine substitutions were generated by site-directed mutagenesis and 
confirmed by sequencing. To generate the SCD1-S expression plas-
mid, SCD1 was PCR amplified from pANT7_cGST-SCD1 (DNASU 
Plasmid Repository, HsCD00631016) and ligated into a pcDNA3.1(–) 
vector bearing an in frame C-terminal S-tag.
The primary antibodies used for immunoblotting include anti-S 
peptide (EMD Millipore), anti-HA (Sigma-Aldrich), anti-ubiquitin 
(FK2; EMD Millipore), anti-tubulin (Abcam), anti-Hrd1 (Bethyl Labo-
ratories), anti-SEL1L (Santa Cruz), anti-CD147 (Santa Cruz), anti-VCP 
(Novus Biologicals), anti-calnexin (Proteintech Group), anti-UBXD8 
(Proteintech Group), anti-AUP1 (Proteintech Group), anti-GAPDH 
(EMD Millipore), anti-SCD1 (Cell Signaling Technology), and anti-
RNF5 (Abcam). Anti-OS-9 and anti-XTP3-B were kind gifts from Ron 
Kopito (Stanford University). Secondary antibodies used were Alexa 
Fluor 680 goat anti-mouse (Life Technologies) and IRDye 800 goat 
anti-rabbit (LI-COR Biosciences).
Chemical reagents used include emetine (Sigma-Aldrich), 
CB5083 (Cleave Biosciences and Cayman Chemical), MLN7243 
(Chemietek), MG132 (Selleck Chemicals), and Bortezomib (Cell 
Signaling Technologies).
Cell culture, transfections, and stable cell line generation
HepG2 cells (American Type Culture Collection) were cultured in 
Roswell Park Memorial Institute 1640 (RPMI; Thermo Fisher Scien-
tific) or DMEM containing 4.5 g/l glucose and l-glutamine (Corning) 
supplemented with 10% fetal bovine serum (FBS; Thermo Fisher 
Scientific and Gemini Bio Products) at 37°C and 5% CO2. Stable 
HEK293 cells expressing S-tagged Hrd1 (To et al., 2017) were 
grown in DMEM supplemented with 10% FBS at 37°C and 5% CO2.
Cells at 60–80% confluence were transfected with the indicated 
plasmids using XtremeGENE HP DNA transfection reagent (Sigma-
Aldrich) following the manufacturer’s protocols. Depletion of SCD1 
in HepG2 cells was accomplished by transfection of SCD1-targeting 
siRNAs from Sigma-Aldrich using RNAiMAX Lipofectamine reagent 
(Thermo Fisher Scientific). siRNA sequences targeting SCD1 include 
5′-GAUAUGCUGUGGUGCUUAA-3′ (siRNA1), 5′-GAUAUCGUC-
CUUAUGACAA-3′ (siRNA2), 5′-GACGAUAUCUCUAGCUCCU-3′ 
(siRNA3), and 5′-GUGAGUACCGCUGGCACAU-3′ (siRNA4). MIS-
SION siRNA Universal Negative Control #1 (SIC001) was used as the 
control siRNA.
Differential fractionation
Cultured cells were collected, washed with ice-cold phosphate-buff-
ered saline (PBS), and incubated in hypotonic lysis medium (HLM: 
20 mM Tris-HCl, pH 7.4, 1 mM EDTA) supplemented with 10 mM 
N-ethylmaleimide (NEM; Thermo Fisher Scientific) on ice for 10 min. 
Cells were then transferred to a 7-ml chilled glass dounce homoge-
nizer and dounced using a tight pestle for 40 strokes. Samples were 
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Digested peptides were desalted via Sep-Pak C18 6-cc cartridges 
(Waters) and lyophilized. Samples were then immunoprecipitated 
using a PTMScan Ubiquitin remnant Motif (K-ε-GG) Kit (Cell Signal-
ing Technologies) according to the manufacturer’s protocols. Briefly, 
lyophilized peptides were dissolved in IAP buffer (50 mM MOPS/
NaOH, pH 7.2, 10 mM Na2HPO4, and 50 mM NaCl) and cleared by 
centrifugation at 10,000 × g for 5 min. For each independent experi-
ment, one tube of K-ε-GG antibody bead conjugates were washed 
four times with PBS, and clarified peptides were incubated with the 
beads for at least 2 h with gentle agitation. Beads were washed 
two times with IAP buffer and three times with MilliQ water and 
eluted twice with 0.15% trifluoroacetic acid. Eluted peptides were 
desalted using C18 StageTips (Thermo Fisher Scientific), dried using 
a Speedvac, and resuspended in 0.1% formic acid (Sigma-Aldrich) 
for analysis by tandem mass spectrometry (LC-MS/MS).
LC-MS/MS analysis
Digested peptides were analyzed by LC-MS/MS on a Q Exactive 
Orbitrap mass spectrometer (Thermo Fisher Scientific) in conjunc-
tion with Proxeon Easy-nLC II HPLC (Thermo Fisher Scientific) and a 
Proxeon nanospray source at the UC Davis Proteomics Core Facility 
as described (To et al., 2017). The resulting MS/MS raw spectral data 
were analyzed using the MaxQuant software platform (version 
1.5.1.0; Cox and Mann, 2008), employing the full UniProt human 
protein sequence database to obtain diGly-modified peptide SILAC 
ratios. A reversed-protein decoy search strategy was also employed 
to minimize false discovery rate. All mass spectrometry files are 
available through the Proteomics Identifications (PRIDE) database 
(Project accession: PXD008842).
Bioinformatic analyses
GO analysis of candidate ERAD substrates was performed using the 
Database for Annotation, Visualization and Integrated Discovery 
(DAVID) v6.8 (Supplemental Table S3; Huang et al., 2009). REVIGO 
(Supek et al., 2011) was then used to simplify and visualize the GO 
terms and the Benjamini corrected p values. GO networks were 
exported from REVIGO and the final networks generated using 
Cytoscape (Shannon et al., 2003). Protein localization and topology 
listed in Supplemental Table S2 were based on UNIPROT 
annotations.
Generation of RNF5 knockout cells
RNF5 knockout lines were generated using the targeting sequence 
5′-CGCTCGCGATTTGGCCCTTC-3′ cloned into PX459 (Addgene; 
plasmid #48139) transfected into HEK293 cells. PX459 without a 
targeting sequence was transfected as a control. Transfected cells 
were selected with 1 µg/ml puromycin (Sigma-Aldrich) for at least 
1 wk. Clonal cell lines were isolated by limited dilution and screened 
for knockout by immunoblotting.
ACKNOWLEDGMENTS
This research was supported by grants from the National Institutes 
of Health (No. R21AG056502 and No. R01GM112948 to J.A.O. and 
No. F32GM119380 to E.H.). We thank Kirill Bersuker for a critical 
reading of the manuscript and Michelle Salemi at the UC Davis 
Proteomics Core Facility for technical assistance.
REFERENCES
Anderson DJ, Le Moigne R, Djakovic S, Kumar B, Rice J, Wong S, Wang J, 
Yao B, Valle E, Kiss von Soly S, et al. (2015). Targeting the AAA ATPase 
p97 as an approach to treat cancer through disruption of protein 
homeostasis. Cancer Cell 28, 653–665.
Bagola K, Mehnert M, Jarosch E, Sommer T (2011). Protein dislocation from 
the ER. Biochim Biophys Acta 1808, 925–936.
Bersuker K, Peterson CWH, To M, Sahl SJ, Savikhin V, Grossman EA, 
Nomura DK, Olzmann JA (2018). A proximity labeling strategy provides 
insights into the composition and dynamics of lipid droplet proteomes. 
Dev Cell 44, 97–112.e7.
Blythe EE, Olson KC, Chau V, Deshaies RJ (2017). Ubiquitin- and ATP-
dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced 
by a mutation that causes multisystem proteinopathy. Proc Natl Acad Sci 
USA 114, E4380–E4388.
Bodnar NO, Rapoport TA (2017). Molecular mechanism of substrate 
processing by the cdc48 atpase complex. Cell 169, 722–735.
Braun S, Matuschewski K, Rape M, Thoms S, Jentsch S (2002). Role of the 
ubiquitin-selective CDC48(UFD1/NPL4)chaperone (segregase) in ERAD 
of OLE1 and other substrates. EMBO J 21, 615–621.
Carvalho P, Goder V, Rapoport TA (2006). Distinct ubiquitin-ligase 
complexes define convergent pathways for the degradation of ER 
proteins. Cell 126, 361–373.
Christianson JC, Olzmann JA, Shaler TA, Sowa ME, Bennett EJ, Richter CM, 
Tyler RE, Greenblatt EJ, Harper JW, Kopito RR (2011). Defining human 
ERAD networks through an integrative mapping strategy. Nat Cell Biol 
14, 93–105.
Christianson JC, Shaler TA, Tyler RE, Kopito RR (2008). OS-9 and GRP94 
deliver mutant α1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase 
complex for ERAD. Nat Cell Biol 10, 272–282.
Christianson JC, Ye Y (2014). Cleaning up in the endoplasmic reticulum: 
ubiquitin in charge. Nat Struct Mol Biol 21, 325–335.
Cox J, Mann M (2008). MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nat Biotechnol 26, 1367–1372.
Ernst R, Claessen JHL, Mueller B, Sanyal S, Spooner E, van der Veen AG, 
Kirak O, Schlieker CD, Weihofen WA, Ploegh HL (2011). Enzymatic 
blockade of the ubiquitin-proteasome pathway. PLoS Biol 8, e1000605.
Fisher E, Lake E, McLeod RS (2014). Apolipoprotein B100 quality control 
and the regulation of hepatic very low density lipoprotein secretion. 
J Biomed Res 28, 178–193.
Foresti O, Rodriguez-Vaello V, Funaya C, Carvalho P (2014). Quality control 
of inner nuclear membrane proteins by the Asi complex. Science 346, 
751–755.
Foresti O, Ruggiano A, Hannibal-Bach HK, Ejsing CS, Carvalho P (2013). 
Sterol homeostasis requires regulated degradation of squalene 
monooxygenase by the ubiquitin ligase Doa10/Teb4. Elife 2, e00953.
Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, 
Chin YR, Shaik S, et al. (2011). mTOR drives its own activation via 
SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. 
Mol Cell 44, 290–303.
Gendron JM, Webb K, Yang B, Rising L, Zuzow N, Bennett EJ (2016). Using 
the ubiquitin-modified proteome to monitor distinct and spatially 
restricted protein homeostasis dysfunction. Mol Cell Proteomics 15, 
2576–2593.
Gill S, Stevenson J, Kristiana I, Brown AJ (2011). Cholesterol-dependent 
degradation of squalene monooxygenase, a control point in cholesterol 
synthesis beyond HMG-CoA reductase. Cell Metab 13, 260–273.
Ginsberg HN, Fisher EA (2009). The ever-expanding role of degradation in 
the regulation of apolipoprotein B metabolism. J Lipid Res 50(Suppl), 
S162–S166.
Grove DE, Fan C-Y, Ren HY, Cyr DM (2011). The endoplasmic reticulum-
associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate RMA1 
E3-dependent degradation of nascent CFTRDeltaF508. Mol Biol Cell 
22, 301–314.
Guerriero CJ, Brodsky JL (2012). The delicate balance between secreted 
protein folding and endoplasmic reticulum-associated degradation in 
human physiology. Physiol Rev 92, 537–576.
Harper JW, Tan MK (2012). Understanding cullin-RING E3 biology through 
proteomics-based substrate identification. Mol Cell Proteomics 11, 
1541–1550.
Hegde RS, Ploegh HL (2010). Quality and quantity control at the 
endoplasmic reticulum. Curr Opin Cell Biol 22, 437–446.
Hitchcock AL, Auld K, Gygi SP, Silver PA (2003). A subset of membrane-
associated proteins is ubiquitinated in response to mutations in the 
endoplasmic reticulum degradation machinery. Proc Natl Acad Sci USA 
100, 12735–12740.
Hoppe T, Matuschewski K, Rape M, Schlenker S, Ulrich HD, Jentsch 
S (2000). Activation of a membrane-bound transcription factor by 
regulated ubiquitin/proteasome-dependent processing. Cell 102, 
577–586.
1030 | E. Y. Huang, M. To, et al. Molecular Biology of the Cell
Prabhu AV, Luu W, Sharpe LJ, Brown AJ (2016). Cholesterol-mediated 
degradation of 7-dehydrocholesterol reductase switches the balance 
from cholesterol to vitamin D synthesis. J Biol Chem 291, 8363–8373.
Qi L, Tsai B, Arvan P (2017). New insights into the physiological role of 
endoplasmic reticulum-associated degradation. Trends Cell Biol 27, 
430–440.
Ramanathan HN, Ye Y (2012). The p97 ATPase associates with EEA1 to 
regulate the size of early endosomes. Cell Res 22, 346–359.
Rape M, Hoppe T, Gorr I, Kalocay M, Richly H, Jentsch S (2001). Mobili-
zation of processed, membrane-tethered SPT23 transcription factor 
by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone. Cell 107, 
667–677.
Ruggiano A, Foresti O, Carvalho P (2014). Quality control: ER-associated 
degradation: protein quality control and beyond. J Cell Biol 204, 
869–879.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, 
Schwikowski B, Ideker T (2003). Cytoscape: a software environment for 
integrated models of biomolecular interaction networks. Genome Res 
13, 2498–2504.
Shi G, Somlo DR, Kim GH, Prescianotto-Baschong C, Sun S, Beuret N, Long 
Q, Rutishauser J, Arvan P, Spiess M, et al. (2017). ER-associated degra-
dation is required for vasopressin prohormone processing and systemic 
water homeostasis. J Clin Invest 127, 3897–3912.
Shimizu Y, Okuda-Shimizu Y, Hendershot LM (2010). Ubiquitylation of an 
ERAD substrate occurs on multiple types of amino acids. Mol Cell 40, 
917–926.
Song BL, Sever N, DeBose-Boyd RA (2005). Gp78, a membrane-anchored 
ubiquitin ligase, associates with Insig-1 and couples sterol-regulated 
ubiquitination to degradation of HMG CoA reductase. Mol Cell 19, 
829–840.
Stevenson J, Huang EY, Olzmann JA (2016). Endoplasmic reticulum-
associated degradation and lipid homeostasis. Annu Rev Nutr 36, 
511–542.
Supek F, Bošnjak M, Škunca N, Šmuc T (2011). REVIGO summarizes and 
visualizes long lists of gene ontology terms. PLoS One 6, e21800.
Tan MK, Lim HJ, Bennett EJ, Shi Y, Harper JW (2013). Parallel SCF adaptor 
capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via 
BACH1 repressor turnover. Mol Cell 52, 9–24.
Tan MK, Lim HJ, Harper JW (2011). SCF(FBXO22) regulates histone H3 
lysine 9 and 36 methylation levels by targeting histone demethylase 
KDM4A for ubiquitin-mediated proteasomal degradation. Mol Cell Biol 
31, 3687–3699.
To M, Peterson CWH, Roberts MA, Counihan JL, Wu TT, Forster MS, 
Nomura DK, Olzmann JA (2017). Lipid disequilibrium disrupts ER 
proteostasis by impairing ERAD substrate glycan trimming and 
dislocation. Mol Biol Cell 28, 270–284.
Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, 
Hewitt SM, Helman LJ, Khanna C, Weissman AM (2007). The ubiquitin 
ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degra-
dation. Nat Med 13, 1504–1509.
Tyler RE, Pearce MMP, Shaler TA, Olzmann JA, Greenblatt EJ, Kopito RR 
(2012). Unassembled CD147 is an endogenous endoplasmic reticulum-
associated degradation substrate. Mol Biol Cell 23, 4668–4678.
Udeshi ND, Mani DR, Eisenhaure T, Mertins P, Jaffe JD, Clauser KR, 
Hacohen N, Carr SA (2012). Methods for quantification of in vivo 
changes in protein ubiquitination following proteasome and 
deubiquitinase inhibition. Mol Cell Proteomics 11, 148–159.
Wojcikiewicz RJH, Pearce MMP, Sliter DA, Wang Y (2009). When worlds 
collide: IP(3) receptors and the ERAD pathway. Cell Calcium 46, 147–153.
Yen HC, Elledge SJ (2008). Identification of SCF ubiquitin ligase substrates 
by global protein stability profiling. Science 322, 923–929.
Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ (2008). Global protein stability 
profiling in mammalian cells. Science 322, 918–923.
Ye Y, Tang WK, Zhang T, Xia D (2017). A mighty “protein extractor” of the 
cell: structure and function of the p97/CDC48 ATPase. Front Mol Biosci 
4, 39.
Younger JM, Chen L, Ren H-Y, Rosser MFN, Turnbull EL, Fan C-Y, Patterson 
C, Cyr DM (2006). Sequential quality-control checkpoints triage mis-
folded cystic fibrosis transmembrane conductance regulator. Cell 126, 
571–582.
Zhong B, Zhang Y, Tan B, Liu T-T, Wang Y-Y, Shu H-B (2010). The E3 ubiqui-
tin ligase RNF5 targets virus-induced signaling adaptor for ubiquitina-
tion and degradation. J Immunol 184, 6249–6255.
Hosokawa N, Wada I, Nagasawa K, Moriyama T, Okawa K, Nagata K (2008). 
Human XTP3-B forms an endoplasmic reticulum quality control scaffold 
with the HRD1-SEL1L ubiquitin ligase complex and BiP. J Biol Chem 
283, 20914–20924.
Huang DW, Sherman BT, Lempicki RA (2009). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat 
Protoc 4, 44–57.
Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, 
Kim H, Brill LM, et al. (2015). Regulation of glutamine carrier proteins 
by RNF5 determines breast cancer response to ER stress-inducing 
chemotherapies. Cancer Cell 27, 354–369.
Ji Y, Kim H, Yang L, Sha H, Roman CA, Long Q, Qi L (2016). The Sel1L-Hrd1 
endoplasmic reticulum-associated degradation complex manages a key 
checkpoint in B cell development. Cell Rep 16, 2630–2640.
Jo Y, Debose-Boyd RA (2010). Control of cholesterol synthesis through 
regulated ER-associated degradation of HMG CoA reductase. Crit Rev 
Biochem Mol Biol 45, 185–198.
Kato H, Sakaki K, Mihara K (2006). Ubiquitin-proteasome-dependent 
degradation of mammalian ER stearoyl-CoA desaturase. J Cell Sci 119, 
2342–2353.
Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, 
Rush J, Comb MJ, et al. (2011). Systematic and quantitative assessment 
of the ubiquitin-modified proteome. Mol Cell 44, 325–340.
Kirkpatrick DS, Weldon SF, Tsaprailis G, Liebler DC, Gandolfi AJ (2005). 
Proteomic identification of ubiquitinated proteins from human cells 
expressing His-tagged ubiquitin. Proteomics 5, 2104–2111.
Kuang E, Okumura CYM, Sheffy-Levin S, Varsano T, Shu VC-W, Qi J, 
Niesman IR, Yang H-J, López-Otín C, Yang WY, et al. (2012). Regulation 
of ATG4B stability by RNF5 limits basal levels of autophagy and influ-
ences susceptibility to bacterial infection. PLoS Genet 8, e1003007.
Lee JN, Gong Y, Zhang X, Ye J (2006). Proteasomal degradation of 
ubiquitinated Insig proteins is determined by serine residues flanking 
ubiquitinated lysines. Proc Natl Acad Sci USA 103, 4958–4963.
Liu T-F, Tang J-J, Li P-S, Shen Y, Li J-G, Miao H-H, Li B-L, Song B-L (2012). 
Ablation of gp78 in liver improves hyperlipidemia and insulin resistance 
by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 16, 
213–225.
Mark KG, Loveless TB, Toczyski DP (2016). Isolation of ubiquitinated 
substrates by tandem affinity purification of E3 ligase-polyubiquitin-
binding domain fusions (ligase traps). Nat Protoc 11, 291–301.
Mark KG, Simonetta M, Maiolica A, Seller CA, Toczyski DP (2014). Ubiquitin 
ligase trapping identifies an SCF(Saf1) pathway targeting unprocessed 
vacuolar/lysosomal proteins. Mol Cell 53, 148–161.
Matsuda N, Suzuki T, Tanaka K, Nakano A (2001). Rma1, a novel type 
of RING finger protein conserved from Arabidopsis to human, is a 
membrane-bound ubiquitin ligase. J Cell Sci 114, 1949–1957.
Morito D, Hirao K, Oda Y, Hosokawa N, Tokunaga F, Cyr DM, Tanaka K, 
Iwai K, Nagata K (2008). Gp78 cooperates with RMA1 in endoplasmic 
reticulum-associated degradation of CFTR∆F508. Mol Biol Cell 19, 
1328–1336.
Mziaut H, Korza G, Ozols J (2000). The N terminus of microsomal ∆9 
stearoyl-CoA desaturase contains the sequence determinant for its rapid 
degradation. Proc Natl Acad Sci USA 97, 8883–8888.
Na CH, Jones DR, Yang Y, Wang X, Xu Y, Peng J (2012). Synaptic protein 
ubiquitination in rat brain revealed by antibody-based ubiquitome 
analysis. J Proteome Res 11, 4722–4732.
Needham PG, Brodsky JL (2013). How early studies on secreted and mem-
brane protein quality control gave rise to the ER associated degradation 
(ERAD) pathway: the early history of ERAD. Biochim Biophys Acta 1833, 
2447–2457.
Ntambi JM, Miyazaki M (2003). Recent insights into stearoyl-CoA desatu-
rase-1. Curr Opin Lipidol 14, 255–261.
O’Connor HF, Lyon N, Leung JW, Agarwal P, Swaim CD, Miller KM, Huibreg-
tse JM (2015). Ubiquitin-activated interaction traps (UBAITs) identify E3 
ligase binding partners. EMBO Rep 16, 1699–1712.
Olzmann JA, Kopito RR, Christianson JC (2013). The mammalian endo-
plasmic reticulum-associated degradation system. Cold Spring Harb 
Perspect Biol 5, a013185.
Ordureau A, Münch C, Harper JW (2015). Quantifying ubiquitin signaling. 
Mol Cell 58, 660–676.
Peng J, Schwartz D, Elias JE, Thoreen CC, Cheng D, Marsischky G, Roelofs 
J, Finley D, Gygi SP (2003). A proteomics approach to understanding 
protein ubiquitination. Nat Biotechnol 21, 921–926.
